Pravin R. Chaturvedi - 05 Apr 2023 Form 4/A - Amendment Insider Report for Jaguar Health, Inc. (JAGX)

Role
Chief Scientific Officer
Signature
/s/ Pravin R. Chaturvedi
Issuer symbol
JAGX
Transactions as of
05 Apr 2023
Net transactions value
$0
Form type
4/A - Amendment
Filing time
19 May 2023, 21:41:39 UTC
Date Of Original Report
20 Apr 2023
Previous filing
28 Dec 2022
Next filing
19 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAGX Common Stock Options Exercise +133 +100% 266 05 Apr 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAGX Restricted stock units Award $0 +133 +13300% $0.000000 134 05 Apr 2023 Common Stock 133 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 On January 23, 2023, the issuer effected a 75-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "January 2023 Reverse Stock Split). Upon effectiveness of the January 2023 Reverse Stock Split, every 75 shares of voting common stock was automatically converted into one share of voting common stock. On September 8, 2021, the issuer effected a 3-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "September 2021 Reverse Stock Split"). Upon effectiveness of the September 2021 Reverse Stock Split, every 3 shares of voting common stock was automatically converted into one share of voting common stock.
F3 On April 20, 2023, the reporting person filed a Form 4 that erroneously indicated that 44 restricted stock units had vested on April 5, 2023 and the reporting person beneficially owned 44 restricted stock units and 88 shares of common stock following such vesting. In fact, 133 restricted stock units had vested on such date and the reporting person beneficially owned 134 restricted stock units and 266 shares of common stock following such vesting.